Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.08M | $207K | $903K | $6.68M | $16.6M | $85.1M | $111M | $26.0M | $38.3M | $400K |
| Revenue growth | — | -97.4% | 336.2% | 639.4% | 148.6% | 412.6% | 30.2% | -76.5% | 47.2% | -99.0% |
| Operating income | -$34.7M | -$63.8M | -$65.0M | -$52.5M | -$56.8M | -$4.60M | $14.5M | -$86.4M | -$43.9M | -$143M |
| Operating margin | -428.9% | -30813.5% | -7200.7% | -785.6% | -342.4% | -5.4% | 13.1% | -332.3% | -114.7% | -35851.3% |
| Net income | -$36.2M | -$65.3M | -$65.3M | -$55.4M | -$68.9M | -$25.7M | $35.4M | -$220M | -$77.4M | -$130M |
| Net margin | -448.0% | -31556.0% | -7235.4% | -829.0% | -415.0% | -30.2% | 31.9% | -844.9% | -202.3% | -32575.5% |
| EPS (diluted) | -$3.89 | -$3.20 | -$2.92 | -$1.22 | -$0.68 | -$0.22 | $0.10 | -$49.76 | -$4.49 | -$5.02 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$19.7M | -$52.0M | -$59.2M | -$51.4M | $34.9M | -$60.4M | -$31.6M | -$51.2M | -$23.7M | -$73.9M |
| Capital expenditures | $586K | $733K | $884K | $47.0K | $815K | $1.08M | $1.20M | $206K | $9.09M | $5.45M |
| Free cash flow | -$20.3M | -$52.8M | -$60.0M | -$51.5M | $34.1M | -$61.5M | -$32.8M | -$51.4M | -$32.8M | -$79.4M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $58.7M | $70.6M | $37.4M | $89.9M | $139M | $114M | $106M | $76.9M | $213M | $125M |
| Total assets | $89.3M | $101M | $44.5M | $99.6M | $165M | $160M | $166M | $305M | $435M | $296M |
| Total liabilities | $34.3M | $49.3M | $49.9M | $91.2M | $183M | $137M | $72.1M | $445M | $442M | $423M |
| Shareholders' equity | $55.0M | $51.8M | -$5.42M | $8.40M | -$18.0M | $22.5M | $93.8M | -$440M | -$6.80M | -$126M |
| Retained earnings | -$152M | -$217M | -$280M | -$336M | -$405M | -$430M | -$395M | -$615M | -$692M | -$822M |
| Shares (wtd avg diluted) | 18.4M | 22.3M | 22.5M | 45.5M | 101M | 114M | 146M | 5.17M | 17.4M | 26.0M |
Every figure is extracted from Cartesian Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.